Zephyr AI

Wishing you a safe and happy Fourth of July! 🇺🇸

At Zephyr AI, our mission is clear: to expand the horizons of precision medicine. We champion the belief that treatments should be finely tuned to every individual. Through our cutting-edge algorithms, we sift through extensive data ranging from genomic profiles to patient records, delivering tailored insights. Our Chief Technology Officer, Jeff Sherman sits down with Virginia Business to discuss our most recent funding and how we are further pioneering advancements in #precisionmedicine. Read more about their conversation below

🔍 There is an urgent unmet need for improved PARPi biomarkers, particularly for patients who fail multiple lines of therapy. We’re excited by the prospect of pairing our technology with a second generation PARPi to expand the zone of sensitivity and thus the patients who can benefit from these treatments. 🧬 Join our Principal Research Scientist, Emily Vucic at American Society of Clinical Oncology (ASCO) to learn more about how we are introducing a AI-first composite biomarkers as a next generation tool for clinical development. Learn more: https://bit.ly/3x8P3FR 🔗 And feel free to explore our ASCO poster for an in-depth view of this latest research, alongside additional company information: https://bit.ly/4c0P3GS #OvarianCancer #Research #PARPInhibitors #ASCO2024

Remembering and honoring all those who have made the ultimate sacrifice for our country this #MemorialDay and every day. 🇺🇸

We're thrilled to be attending American Society of Clinical Oncology (ASCO) 2024 and connecting with industry leaders about novel developments shaping the oncology landscape. Visit our poster presentation to hear Emily Vucic share our findings on the "Evaluation of a Novel Machine Learning Method for PARP Inhibitor Sensitivity Prediction Using Real-World Data" - June 3, 2024 from 9-12pm CDT! And meet the rest of the Zephyr team! #ASCO2024 #machinelearning #RWD

We are delighted to announce the appointment of John Applegate as our new Chief Financial Officer! Bringing with him over 25 years of experience in finance and a proven commitment to driving #innovation within the healthcare sector, John is a valuable addition to our #team here at Zephyr AI. His strategic insight and seasoned expertise will be essential in guiding our financial strategy as we continue our mission to democratize precision medicine in oncology. Welcome, John! Read More 👉 https://bwnews.pr/3QP5s9j

Check out our recent spotlight in BioSpace! 🌟 Our Chief Scientific Officer, Rachael Brake, sees generative AI moving to support specific areas and processes in drug development where it can have the most effect on patient outcomes, time or cost.   Read the article below! #patientoutcomes #healthtech #precisionmedicine

At Zephyr AI, we are dedicated to democratizing precision medicine so more patients benefit. By harnessing insights from diverse, multi-modal datasets, we identify the right treatment at the right time for the right patient. This means faster, more effective, and cost-efficient solutions for patients worldwide. Let's come together during Cancer Research Month to support a paradigm shift and expand hope to more lives. #cancerresearch #oncology #machinelearning #precisionmedicine

💥 At Zephyr, we are pioneering an innovative AI platform designed to transform the way cancer and cardiometabolic diseases are treated. 🔍 Are you or someone you know passionate about making a real impact in Precision Medicine? 🚀 We're #hiring! Discover our current job openings and apply today to be part of a #team that values innovation, collaboration, and growth. Head over to zephyrai.bio/careers

Get ready to witness Dillon Tracy and the Zephyr team's cutting-edge discoveries firsthand. Looking forward to seeing you today at the American Association for Cancer Research! More information below! #AACR24